Eric D. Shaff - 15 Aug 2026 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Aug 2026, 17:27:35 UTC
Prior SEC filing
10 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Thomas J. DesRosier, Attorney-in-Fact for Eric D. Shaff

Key filing fact

Eric D. Shaff filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 18 Aug 2026.

Key facts

  • This page summarizes Eric D. Shaff's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 18 Aug 2026, 17:27.

Change

  • Previous filing in this sequence was filed on 10 Jul 2026.
  • Current net transaction value: -$1,197.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643734 Primary reporting owner

Shaff Eric D.

Relationship
Director
Address
C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Signature
/s/ Thomas J. DesRosier, Attorney-in-Fact for Eric D. Shaff
Signature date
18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MCRB transaction

Common Stock

Options Exercise

Transaction value
Shares
+722
Change %
+6%
Price
Shares after
12,762
Date
15 Aug 2026
Ownership
Direct
Footnotes
F1
MCRB transaction

Common Stock

Sale

Transaction value
$1,197
Shares
-263
Change %
-2.1%
Price
$4.55
Shares after
12,499
Date
17 Aug 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MCRB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-390
Change %
-33%
Price
$0.000000*
Shares after
783
Date
15 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
390
Exercise price
Footnotes
F1, F3
MCRB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-332
Change %
-14%
Price
$0.000000*
Shares after
1,993
Date
15 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
332
Exercise price
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Footnote F3

The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Footnote F4

The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .